CINECA IRIS Institutional Research Information System

GALIMBERTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.293
EU - Europa 11.923
AS - Asia 4.111
AF - Africa 351
SA - Sud America 58
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 17
Totale 41.782
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.364
IT - Italia 4.762
CA - Canada 2.916
SE - Svezia 2.230
CN - Cina 2.100
BG - Bulgaria 1.143
PL - Polonia 986
DE - Germania 813
SG - Singapore 704
GB - Regno Unito 553
VN - Vietnam 493
TR - Turchia 446
UA - Ucraina 387
FI - Finlandia 360
CI - Costa d'Avorio 210
CH - Svizzera 172
IN - India 152
HK - Hong Kong 136
FR - Francia 135
RU - Federazione Russa 128
BE - Belgio 82
SN - Senegal 81
AT - Austria 46
NG - Nigeria 39
BR - Brasile 37
NL - Olanda 35
JP - Giappone 27
CZ - Repubblica Ceca 23
AU - Australia 22
EG - Egitto 16
EU - Europa 16
GR - Grecia 15
KR - Corea 13
ES - Italia 12
RO - Romania 11
IE - Irlanda 10
NZ - Nuova Zelanda 7
CL - Cile 6
IR - Iran 6
EC - Ecuador 5
ID - Indonesia 5
IL - Israele 5
MX - Messico 5
BT - Bhutan 4
DK - Danimarca 4
IQ - Iraq 3
PE - Perù 3
PT - Portogallo 3
SC - Seychelles 3
TW - Taiwan 3
AR - Argentina 2
BO - Bolivia 2
CR - Costa Rica 2
EE - Estonia 2
HR - Croazia 2
HU - Ungheria 2
KZ - Kazakistan 2
NI - Nicaragua 2
PA - Panama 2
PR - Porto Rico 2
RS - Serbia 2
SA - Arabia Saudita 2
TH - Thailandia 2
UZ - Uzbekistan 2
A1 - Anonimo 1
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
CO - Colombia 1
ET - Etiopia 1
GY - Guiana 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MD - Moldavia 1
MT - Malta 1
MY - Malesia 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UY - Uruguay 1
Totale 41.782
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.165
Fairfield 2.534
Ann Arbor 2.397
Montreal 2.302
Serra 2.005
Houston 1.992
Chandler 1.818
Ashburn 1.273
Milan 1.204
Sofia 1.140
Seattle 1.099
Beijing 903
Wilmington 871
Cambridge 829
New York 725
Princeton 635
Ottawa 583
Jacksonville 565
Lawrence 458
Medford 440
Izmir 422
Nanjing 310
Singapore 264
Des Moines 232
Abidjan 210
Dearborn 198
Florence 196
Dong Ket 169
San Diego 167
Bern 159
Nanchang 155
Rome 138
London 129
Hong Kong 126
Redwood City 120
Boardman 103
Jüchen 98
Bremen 94
Hebei 90
Shenyang 82
Dakar 81
Lancaster 81
Brussels 80
Kunming 73
Pisa 73
Ogden 71
Changsha 68
Hefei 57
Frankfurt am Main 55
Los Angeles 55
Boulder 49
Jiaxing 48
Westminster 46
Norwalk 45
Vienna 42
Lagos 39
Alessandria 38
Hangzhou 38
Chicago 37
Washington 36
Pune 35
Tianjin 34
Guangzhou 31
San Jose 31
Düsseldorf 30
Orange 27
Phoenix 24
Auburn Hills 21
Chengdu 21
Detroit 21
Hyderabad 20
Falls Church 19
Nürnberg 18
Costa Mesa 15
Lanzhou 15
Livorno 14
Duncan 12
Fuzhou 12
Jinan 12
Monza 12
San Francisco 12
Hamilton 11
Helsinki 11
Kilburn 11
New Delhi 11
Wuhan 11
Changchun 10
Palermo 10
Sydney 10
Council Bluffs 9
Fremont 9
Leawood 9
Olomouc 9
Zhengzhou 9
Indiana 8
Kocaeli 8
Tappahannock 8
Tokyo 8
Dallas 7
Edinburgh 7
Totale 32.124
Salva come PNG Salva come JPEG
Nome #
EFFICACY AND TOXICITY PROFILES OF LOW-DOSE THALIDOMIDE AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS AFTER DOUBLE OR TRIPLE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. 3.357
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 205
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 186
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 186
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 170
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 167
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 162
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 160
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 160
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology 159
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 158
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 158
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 156
Characterization of Ph-negative abnormal clones emerging during imatinib therapy 155
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 154
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 151
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 150
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 149
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 148
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 146
Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA 146
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 142
Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma. 141
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 141
Correspondence between salivary proteomic pattern and clinical course in primary Sjogren syndrome and non-Hodgkin's lymphoma: a case report 141
Unexpected cardiotoxicity in haematological bortezomib treated patients 139
Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report., LEUKEMIA RESEARCH,pp 00,tot.pag 00,tot. autori 7,2007 139
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 139
WT1 GENE EXPRESSION IS SIGNIFICANTLY INHIBITED BY VORINOSTAT AND BORTEZOMIB IN MYELOPROLIFERATIVE/MYELODISPLASTIC DISEASES 137
Expression of MDR1, MRP, TOPOISOMERASE-IIa, TOPOISOMERASE-IIb and GSTp in acute leukemias. 135
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 134
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 134
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 133
90y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group 133
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 133
Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA 131
PS-341 (Bortezomid) inhibits both proliferation of megakaryoblastic cells in vitro and MK colonies production in patients affected by idiopathic myelofibrosis 129
PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells 129
BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY. 128
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 128
Panobinostat for the treatment of acute myelogenous leukemia 128
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 128
Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. 127
Actin polymerization in neutrophils from donors of peripheral blood stem cells: divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor 127
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib 127
Gelatin/PLLA sponge-like scaffolds allow proliferation and osteogenic differentiation of human mesenchymal stromal cells 127
P112 gene expression patterns in MDS with del5q before and during lenalidomide treatment 125
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. 125
HISTONE DEACETYLASE INHIBITOR ITF2357 EXERT SIGNIFICANT ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS ON THE P39 CELL LINE: A GENE EXPRESSION STUDY 124
Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure 124
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 124
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 124
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment 124
Good manufacturing practice-grade fibrin gel is useful as a scaffold for human mesenchymal stromal cells and supports in vitro osteogenic differentiation 123
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma 123
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 123
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview 123
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 123
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 122
PLATELET-DERIVED GROWTH FACTOR BETA RECEPTOR (PDGFRB) GENE IS REARRANGED IN A SIGNIFICANT PERCENTAGE OF MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE 122
Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. 121
Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma 121
R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL) 121
Low dose 2-CdA schedule activity in splenic marginal zone lymphomas 120
Other mechanisms to explain the role of reduced folate carrier in cancer 120
Predictive role of WT1 and RPS14 expression in patients affected by myelodysplastic syndromes receiving azacitidine 120
Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis 119
Suspension of Bone Marrow-Derived Undifferentiated Mesenchymal Stromal Cells for Repair of Superficial Digital Flexor Tendon in Race Horses. Tissue Eng. 2007 Oct 5 119
PEG-Filgrastim activity on granulocyte functions 119
Unusual association of endometrial cancer and multiple myeloma 119
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 119
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 119
Hairy Cell Leukemia. 118
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients 118
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 118
Clinical Applications of Nuclear Medicine: Multiple Myeloma 118
Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission 117
Early Diagnosis of Neutropenic Enterocolitis by Ultrasound Sonography. 117
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in ch 117
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study 117
MDR1 polymorphism influences the outcome of multiple myeloma patients 117
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 117
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 117
Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy. 116
SAHA INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN A MEGAKARYOBLASTIC CELL LINE AND SYNERGISTICALLY INTERCATCS WITH THE PORTEASOME INHIBITOR BORTEZOMIB. 116
Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study 116
Missense mutations in the PML-RAR alpha ligand binding domain in ATRA resistant Arsenic trioxide sensitive relapsed acute promyelocytic leukemia 116
MDR1 polymorphism influences the outcome of multiple myeloma patients 116
MDS: An Integrated Workup for a Correct Diagnosis 116
A myeloablative allograft after rejection of two consecutive nonmyeloablative transplants from two different HLA identical siblings 115
A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13) 115
Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study 114
Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk 114
Dose-dependent induction of apoptosis by R-apomorphine in CHO-K 1 cell line in culture 114
Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis. 114
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 114
Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). 113
How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases 113
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 113
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib 113
Totale 16.318
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.956
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.630 0 513 1.956 456 653 750 863 558 682 481 578 140
2020/20213.535 261 181 204 153 287 144 393 287 343 214 380 688
2021/20225.477 163 363 141 344 923 661 159 235 447 154 364 1.523
2022/20235.801 916 813 385 550 576 701 54 463 876 45 356 66
2023/20248.144 607 561 562 370 720 803 232 106 67 3.358 187 571
2024/202573 66 7 0 0 0 0 0 0 0 0 0 0
Totale 42.642